TY  - JOUR
AU  - Jorgačević, B
AU  - Vučević, D
AU  - Đuričić, Ivana
AU  - Šobajić, Slađana
AU  - Mladenović, Dušan
AU  - Vesković, M
AU  - Vukićević, R.J
AU  - Radosavljević, Tatjana S.
PY  - 2017
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2915
AB  - We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n = 6); group fed with HFD 20 weeks (HF; n = 6); group fed with control diet and treated with rimonabant after 18 weeks (R; n = 9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n = 10). Rimonabant (10 mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p  lt  0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p  lt  0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p  lt  0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile.
PB  - Elsevier Ireland Ltd
T2  - Chemistry and Physics of Lipids
T1  - The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease
VL  - 204
SP  - 85
EP  - 93
DO  - 10.1016/j.chemphyslip.2017.03.009
ER  - 

@article{
author = "Jorgačević, B and Vučević, D and Đuričić, Ivana and Šobajić, Slađana and Mladenović, Dušan and Vesković, M and Vukićević, R.J and Radosavljević, Tatjana S.",
year = "2017",
abstract = "We used rimonabant to investigate the role of CB1 receptor on hepatic FFAs profile during NAFLD. Male mice C57BL/6 were divided into: control group fed with control diet 20 weeks (C; n = 6); group fed with HFD 20 weeks (HF; n = 6); group fed with control diet and treated with rimonabant after 18 weeks (R; n = 9); group fed with HFD and treated with rimonabant after 18 weeks (HFR; n = 10). Rimonabant (10 mg/kg) was administered daily to HFR and R group by oral gavage. Rimonabant decreased liver palmitic acid proportion in HFR group compared to HF group (p  lt  0.05). Liver stearic and oleic acid proportions were decreased in R group compared to control (p  lt  0.01 respectively). Rimonabant increased liver linoleic and arachidonic acid proportions in HFR group compared to HF group (p  lt  0.01 respectively). CB1 blockade may be useful in the treatment of HFD-induced NAFLD due to modulation of plasma lipid and hepatic FFA profile.",
publisher = "Elsevier Ireland Ltd",
journal = "Chemistry and Physics of Lipids",
title = "The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease",
volume = "204",
pages = "85-93",
doi = "10.1016/j.chemphyslip.2017.03.009"
}

Jorgačević, B., Vučević, D., Đuričić, I., Šobajić, S., Mladenović, D., Vesković, M., Vukićević, R.J,& Radosavljević, T. S.. (2017). The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. in Chemistry and Physics of Lipids
Elsevier Ireland Ltd., 204, 85-93.
https://doi.org/10.1016/j.chemphyslip.2017.03.009

Jorgačević B, Vučević D, Đuričić I, Šobajić S, Mladenović D, Vesković M, Vukićević R, Radosavljević TS. The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease. in Chemistry and Physics of Lipids. 2017;204:85-93.
doi:10.1016/j.chemphyslip.2017.03.009 .

Jorgačević, B, Vučević, D, Đuričić, Ivana, Šobajić, Slađana, Mladenović, Dušan, Vesković, M, Vukićević, R.J, Radosavljević, Tatjana S., "The effect of cannabinoid receptor 1 blockade on hepatic free fatty acid profile in mice with nonalcoholic fatty liver disease" in Chemistry and Physics of Lipids, 204 (2017):85-93,
https://doi.org/10.1016/j.chemphyslip.2017.03.009 . .